ClinicalTrials.gg
CompletedNCT07687368CGM-UCI23Updated Jul 7, 2026

Clinical Trial Protocol for Continuous Glucose Monitoring in Critical Care

An interventional study of Continuous Glucose Monitoring and Conventional Glucose Measurement in Critical Care Nursing, Critical Illness and Critical Care, Intensive Care, sponsored by Institut d'Investigacions Biomèdiques August Pi i Sunyer. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.

Primary conditionCritical Illness(the registry's first term)UnverifiedIs this wrong?Critical Illness is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Institut d'Investigacions Biomèdiques August Pi i Sunyer · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jun 2025, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

High blood glucose levels (hyperglycaemia) are very common in patients admitted to intensive care units (ICUs) and are associated with worse health outcomes. Traditionally, glucose levels in critically ill patients are monitored using point-of-care blood glucose (POC-G) testing (fingerstick, arterial, or venous blood samples), which may require multiple measurements each day.

Continuous glucose monitoring (CGM) is a technology that measures glucose levels continuously throughout the day and night, providing real-time information and alerts when glucose levels are too high or too low. Previous studies have shown that CGM can be used safely in critically ill patients and may reduce the number of blood glucose tests required. However, more evidence is needed to determine whether CGM improves glucose control and patient outcomes in the ICU.

The purpose of this study is to compare CGM-based glucose management with standard point-of-care glucose testing in critically ill patients with hyperglycaemia admitted to the Hospital Clínic of Barcelona. Participants will be randomly assigned to one of two groups. In the experimental group, healthcare professionals will use real-time CGM data to make glucose management decisions. In the control group, glucose management will be based on standard point-of-care testing, while CGM data will be collected in the background for later analysis.

The study will evaluate whether CGM improves the amount of time that glucose levels remain within the target range, reduces episodes of high and low glucose, decreases the number of blood glucose tests required, and influences patient outcomes such as complications, hospital readmissions, and mortality up to 90 days after ICU discharge.

Researchers hope that the results of this study will help determine whether CGM should become part of routine ICU care, improving patient safety, reducing the burden of glucose monitoring, and supporting more efficient clinical decision-making.

02

Conditions studied

  • Critical Care Nursing
  • Critical Illness
  • Critical Care, Intensive Care
  • Hyperglycaemia
  • Glucose Control
  • Continuous Glucose Monitoring

Browse trials for

03

In context

Critical Illness Unverified

1,787 studies on the registry are indexed under Critical Illness; 445 are open to participants now.

This study's enrollment of 400 is above the median of 90 across 930 interventional studies indexed under Critical Illness.

Browse Critical Illness studies →

Lead sponsor

Institut d'Investigacions Biomèdiques August Pi i Sunyer is the lead sponsor of 9 studies on the registry; 4 are open to participants now.

Compared within Critical Illness, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or over
  • Stay in ICU and/or intermediate care
  • Blood glucose levels >180 mg/dL (10 mmol/L).

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • for the use of CGM (such as skin issues or allergies to adhesives)
  • End-of-life process
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
400 participants (actual)

Study arms

  • Sham comparator
    Conventional Glucose Measurement

    Participants receive standard glycemic management according to ICU standard practice. Capillary blood glucose is the primary method used for insulin dose adjustment and is complemented, when clinically indicated, by arterial or venous blood glucose measurements. On average, approximately six blood glucose measurements are performed per day; however, the frequency may be increased or decreased according to the prescribed treatment regimen, insulin requirements, and the patient's clinical condition during ICU admission. CGM is used throughout the study period to collect glucose data. In this control arm, CGM data are blinded to healthcare professionals and are not used for clinical decision-making, serving as a sham intervention for study comparison purposes. All therapeutic decisions, including insulin dose adjustments, are based exclusively on conventional blood glucose measurements according to standard ICU practice.

    Device: Conventional Glucose Measurement

  • Experimental
    Continuous Glucose Monitoring Group

    Participants randomized to the experimental group will receive glucose management guided by a CGM system. A CGM sensor will be inserted on the upper arm or abdomen and will provide real-time glucose measurements every 5 minutes. Glucose values, trends, and alerts for hyperglycaemia and hypoglycaemia will be available to the clinical team and used to support glycaemic management decisions during the ICU stay. The CGM system will be configured with predefined glucose alerts and predictive hypoglycaemia alarms. Healthcare professionals may perform additional point-of-care glucose measurements when clinically indicated, including confirmation of hypoglycaemia, extreme glucose values, or during intravenous insulin therapy according to safety criteria.

    Device: Continuous Glucose Monitoring

Interventions

  • DeviceContinuous Glucose Monitoring

    CGM uses a subcutaneous sensor inserted into the upper arm or abdomen to measure interstitial glucose every 5 minutes. The system provides real-time glucose values, trends, and configurable alerts for hyperglycaemia and hypoglycaemia to support glycaemic management. Point-of-care blood glucose measurements may be performed when clinically indicated for confirmation of hypoglycaemia, extreme glucose values, or according to institutional safety protocols during intravenous insulin therapy.

    Also known as: CGM, CGM Guided

  • DeviceConventional Glucose Measurement

    Conventional glucose monitoring consists of capillary blood glucose measurements as the primary method for insulin dose adjustment according to standard ICU practice, complemented by arterial or venous blood glucose measurements when clinically indicated, all know as POC-G measurements. Glucose is typically measured approximately six times daily, with frequency adjusted according to clinical condition and insulin requirements. During the study, a CGM device is worn only for glucose data collection; CGM values remain blinded to healthcare professionals and are not used for clinical decision-making. All therapeutic decisions are based exclusively on conventional blood glucose measurements.

    Also known as: POC-G Group, Conventional Group, Sham Group

06

What researchers measure

Primary outcomes

  1. Time in Range

    Percentage of time that glucose values remain within the target range of 70-180 mg/dL (3.9-10.0 mmol/L), measured by continuous glucose monitoring.

    Time frame: During ICU stay (up to 10 days or until ICU discharge, death, or sensor removal).

Secondary outcomes

  1. Time Above Range (TAR)

    Percentage of time that glucose values are above 180 mg/dL (10.0 mmol/L), measured by continuous glucose monitoring.

    Time frame: During ICU stay (up to 10 days or until ICU discharge, death, or sensor removal).

  2. Time Below Range (TBR)

    Percentage of time that glucose values are below 70 mg/dL (3.9 mmol/L), measured by continuous glucose monitoring.

    Time frame: During ICU stay (up to 10 days or until ICU discharge, death, or sensor removal).

  3. Number of Point-of-Care Glucose Measurements

    Total number of point-of-care glucose measurements performed during ICU admission.

    Time frame: During ICU stay (up ICU discharge or death)

  4. Hospital Readmissions

    Number of participants readmitted to the hospital following discharge from the ICU.

    Time frame: Up to 90 days after ICU discharge.

  5. Morbidity at 90 Days

    Presence of illness, disease, or complications affecting health status, quality of life, or functional ability that occur during hospitalization or within 90 days following ICU discharge.

    Time frame: Up to 90 days after ICU discharge.

  6. Mean Absolute Relative Difference (MARD)

    Accuracy of continuous glucose monitoring assessed by the Mean Absolute Relative Difference (MARD) between continuous glucose monitoring values and paired point-of-care glucose measurements. MARD will be calculated as the mean of the absolute relative differences between paired glucose values and expressed as a percentage.

    Time frame: During ICU stay (up to 10 days or until ICU discharge, death, or sensor removal).

  7. Diabetes Technology Society (DTS) Error Grid Analysis

    Clinical risk associated with continuous glucose monitoring accuracy assessed using the Diabetes Technology Society (DTS) Error Grid. Paired continuous glucose monitoring and point-of-care glucose values will be classified according to risk categories, and the proportion of values within the no-risk and slight-risk zones will be reported.

    Time frame: During ICU stay (up to 10 days or until ICU discharge, death, or sensor removal).

07

Study locations

1 site
  • Carrer de Villarroel, 170
    Barcelona, Catalonia 08036, Spain
08

References and documents

Publications

  • Panero-Moreno M, Muxella-Roson M, Dube-Llobet G, Cabrerizo-Jimenez M, Guix-Comellas EM, Villamor-Ordozgoiti A, Marsa-Perez N. The use of continuous glucose monitoring: A scoping review of accuracy, feasibility and nursing workload reduction in intensive care setting. Enferm Intensiva (Engl Ed). 2025 Jul-Sep;36(3):500534. doi: 10.1016/j.enfie.2025.500534. PubMed 40883056 ↗
  • Faulds ER, Boutsicaris A, Sumner L, Jones L, McNett M, Smetana KS, May CC, Buschur E, Exline MC, Ringel MD, Dungan K. Use of Continuous Glucose Monitor in Critically Ill COVID-19 Patients Requiring Insulin Infusion: An Observational Study. J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4007-e4016. doi: 10.1210/clinem/dgab409. PubMed 34100545 ↗
  • Agarwal S, Mathew J, Davis GM, Shephardson A, Levine A, Louard R, Urrutia A, Perez-Guzman C, Umpierrez GE, Peng L, Pasquel FJ. Continuous Glucose Monitoring in the Intensive Care Unit During the COVID-19 Pandemic. Diabetes Care. 2021 Mar;44(3):847-849. doi: 10.2337/dc20-2219. Epub 2020 Dec 23. PubMed 33361145 ↗
  • Rijkenberg S, van Steen SC, DeVries JH, van der Voort PHJ. Accuracy and reliability of a subcutaneous continuous glucose monitoring device in critically ill patients. J Clin Monit Comput. 2018 Oct;32(5):953-964. doi: 10.1007/s10877-017-0086-z. Epub 2017 Dec 7. PubMed 29218549 ↗
  • Ammar MA, Ammar AA, Wee T, Deshpande R, Band M, Akhtar S. Relationship Between Glucose Time in Range in Diabetic and Non-Diabetic Patients and Mortality in Critically Ill Patients. J Intensive Care Med. 2022 Dec;37(12):1625-1633. doi: 10.1177/08850666221098383. Epub 2022 May 2. PubMed 35491687 ↗
  • American Diabetes Association Professional Practice Committee for Diabetes*. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026 Jan 1;49(Suppl 1):S183-S215. doi: 10.2337/dc26-S009. PubMed 41358900 ↗
  • Panero-Moreno M, Carbonell-Sabate C, Conesa-Gonzalez R, Risco-Patino L, Guix-Comellas EM, Villamor-Ordozgoiti A, Cordon-Arnau T. Continuous glucose monitoring in a critically ill patient with extracorporeal membrane oxygenation (ECMO), intra-aortic balloon pump, and continuous renal replacement therapy: Case report. Enferm Intensiva (Engl Ed). 2026 Apr-Jun;37(2):500589. doi: 10.1016/j.enfie.2026.500589. Epub 2026 Apr 11. PubMed 41967195 ↗
  • Panero-Moreno M, Guix-Comellas EM, Villamor-Ordozgoiti A. Clinical trial protocol for continuous glucose monitoring in critical care at Hospital Clinic of Barcelona (CGM-UCI23). Nurs Crit Care. 2025 May;30(3):e13198. doi: 10.1111/nicc.13198. Epub 2024 Oct 28. PubMed 39467825 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD that underlie the results reported in publications, after anonymization, will be available to qualified researchers upon reasonable request. Data sharing will require approval from the principal investigator and the relevant ethics committee and will comply with applicable data protection regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Beginning 12 months after publication of the study results and ending 5 years after publication.

Access criteria: Anonymized IPD underlying the published results to researchers upon reasonable request. Requests will be reviewed by the principal investigator and may require approval from the relevant ethics committee and the sponsoring institution. Data will be provided for scientifically sound research purposes and in accordance with applicable data protection regulations. Access will be granted through a secure data-sharing process following the execution of an appropriate data access agreement.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Jun 2026, 11 months.

Of 405 non-industry interventional studies with no phase under Critical Illness, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 11 months is below that.

Counting every sponsor, half of 409 studies reached it within 21 months; a quarter within 11 and three quarters within 40.

Critical Illness covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2026
First posted
Jul 7, 2026
StartActual
Jun 14, 2025
Primary completionActual
Jun 1, 2026
CompletionActual
Jun 1, 2026
Last update
Jul 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07687368
Lead sponsor
Institut d'Investigacions Biomèdiques August Pi i Sunyer
Responsible party
Marc Pañero Moreno (Principal Investigator, Institut d'Investigacions Biomèdiques August Pi i Sunyer) — Principal investigator
First posted
Jul 7, 2026
Start date
Jun 14, 2025
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026
Last update
Jul 7, 2026

Study contacts

Eva M Guix-Comellas, PhD
study director · University of Barcelona
Alberto Villamor-Ordozgoiti, PhD
study director · Hospital Clínic of Barcelona

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion